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ABSTRACT
Cancer is one of the most prominent diseases resulting in death, thus the need for early detection
remains essential to its treatments. It is usually associated with DNA methylation changes during
tumorigenesis. While many studies focus on euchromatin, some studies have looked at the
methylation changes in heterochromatin, since the methylation changes of repetitive elements is
common and they contribute to karyotypic instability leading to enhanced chances for more
mutations in tumor progression. Using bisulfite PCR and HC21 as a model, this study examines
the DNA methylation changes of three repetitive elements in prostate cancer, NBL2, satellite I
subfamilies, and gamma satellite. NBL2 is a 1.4 kb tandem repeat located on chromosomes 9,
13, 14, 15, and 21. A previous study of NBL2 suggested that it is located near the centromeres
and it can be either hypo or hypermethylated in cancer, making it tumor-specific. Results from
this study using hybrid cell mapping and mapping via Genome Browser suggest that NBL2 is
located 1Mb farther from the centromere than previously thought. Preliminary data indicates that
NBL2 is not a viable biomarker for prostate cancer due to its high methylation patterns across all
cell templates used. Satellite I subfamilies methylation patterns were not examined due to the
failed amplification process. Gamma satellite is a tandem array that contains 220bp GC-rich
repeating units that can form 10-200 kb clusters found in the pericentromeric regions of all
chromosomes. Previous studies suggest that gamma has an anti-silencing activity to prevent the
spread of heterochromatin into the long arm, and it is hypermethylated in cancer. This study
found gamma satellite to be hypermethylated in prostate cancer and normal cells. This suggests
x

that the stable DNA methylation of gamma satellite may play a major role in the anti-silencing
boundary rather than histone modifications. Overall, both NBL2 and gamma satellite do not
seem to be potential biomarkers for prostate cancer due to their stable hypermethylation patterns
in different cell types.

xi

CHAPTER ONE
INTRODUCTION
Heterochromatin
The Human Genome Project focused on the euchromatic regions of the genome, and did not
include the heterochromatic regions that constitute 10-15% of the genome. Heterochromatin is
found in the centromeres, telomeres, and the short arms of the acrocentric chromosomes (13, 14,
15, 21, and 22) (deCapoa et al., 1973), and is associated with tightly compacted repetitive DNA
sequences that are transcriptionally inactive. Heterochromatin is characterized by the presence of
H3K9me and H3K27me histone modifications as well as histone hypoacetylation, all of which
result in chromatin compaction. The presence of histone methyltransferases in turn recruits
DNA methyltransferases 3A and 3B to methylate the DNA CpG di-nucleotides in these regions
(Bird, 2002). This reinforces the closed DNA conformation, which prohibits the accessibility of
transcription factors to promoters, thereby silencing genes (Ng and Bird, 1999).
The two types of heterochromatin in the genome are constitutive and facultative.
Constitutive heterochromatin, which contains no genes, is always inactive and predominately
contains H3K9me3. However, facultative heterochromatin contains H3K27me3 and contains
genes that are silent in only certain cell types. Due to the presence of genes in facultative
heterochromatin, constitutive heterochromatin is more static than facultative heterochromatin
(Saksouk, 2015). Both types of heterochromatin are found in the pericentromeric regions,
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centromeres, and telomeres. Facultative heterochromatin can also be found in additional
chromosomal regions throughout the genome (Oberdoerffer and Sinclair, 2007).
Studies have shown that heterochromatin is essential for genomic stability. DNA
sequences present in heterochromatic regions of the genome are usually tandem repeats. Despite
the fact that these repetitive elements don’t code for proteins, they are essential for maintaining
chromosome function and genome integrity, specifically at centromeres and telomeres (Horard et
al. 2009). The repetitive DNA repeats in heterochromatin are required for proper sisterchromatid cohesion and chromosomal segregation. Heterochromatin is also important in
inhibiting recombination between homologous repeats within the chromosome and between
chromosomes (Grewal and Moazed, 2003).
DNA Methylation
DNA methylation is one of the many mechanisms responsible for inhibiting transcription.
The genome’s methylation patterns result from the activity of de novo methyltransferases 3A and
3B acting on the early embryo that is initially globally demethylated (Okano et al., 1999). DNA
methylation functions to silence transcription by adding a 5-methyl group to cytosine in a CpG
dinucleotide. The human genome is 41% G+C (Antonarakis et al., 2010) with 28 million CpG
sites (Lovkvist et al., 2016). About 70-80% of the CpG dinucleotide sites are methylated
(Ehrlich, 1982). While the majority of the CpG sites are methylated, non-methylated CpGs are
observed in embryonic cells and CpG islands near promoters (Bird, 2002). Housekeeping genes
and many developmentally regulated genes are associated with CpG islands (Andel, 1999). Since
these genes need to be functional, their location next to unmethylated regions allows them to be
expressed.
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High levels of DNA methylation are a necessity for transcription inhibition in genomic
regions containing clusters of repetitive DNA (Selker, 1999). DNA methylation is responsible
for stably maintaining such genomic regions in an inactive conformation. As an example, DNA
methylation is critical in maintaining X chromosome inactivation since treatment with a
demethylating agent relieves the inactivation (Mohandas et al., 1981, Graves, 1982, Venolia et
al., 1982). DNA methylation inhibits transcription by making DNA stay in the closed chromatin
configuration. This process is activated when methylated DNA wrapped around nucleosomes
recruits proteins with methyl-CpG binding domains, which in turn recruit histone methyl
transferases and histone deacetylases. These enzymes ensure the closed DNA chromatin
configuration, which prevents DNA from binding to transcription factors to initiate transcription
(Curradi et al., 2002). Thus, DNA methylation plays a significant role in heterochromatin in
keeping the silent genes and repetitive elements from being expressed.
Cancer
Any deviations from the normal global DNA methylation pattern results in changes in
gene expression, which usually means disease. Cancer is the second leading cause of death
worldwide and developing treatments points to the need for a greater understanding of the DNA
methylation changes associated with cancer. Changes in DNA methylation patterns of repetitive
elements are one of the many epigenetic changes associated with cancer (Ehrlich, 2002). In
normal tissue, repetitive elements are usually hypermethylated at CpG sites, which serves to
stably repress transcription of these regions (Suva et al., 2013). Many studies emphasize the
hypermethylation at CpG islands of promoters of tumor suppressor genes in cancer (Jones et al.,
2012). However, hypomethylation of various heterochromatic repetitive elements in cancer cells
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is common and contributes to karyotypic instability leading to enhanced chances for more
mutations in tumor progression (Ehrlich, 2002).
Cancer is associated with alterations in DNA methylation that can be hypomethylation,
hypermethylation, or both (Kullis and Esteller, 2010). Hypermethylation is of much interest due
to the fact that it occurs in CpG islands, next to gene promoters in euchromatin. CpG islands are
usually unmethylated, allowing the transcription of genes. However, in cancer cells CpG islands
have been shown to be hypermethylated by many studies. Genes associated with CpG islands
include tumor suppressor genes, so when the CpG islands are methylated, tumor suppressor
genes cannot be transcribed (Ohtani-Fujita et al., 1993). The extents to which CpG islands are
methylated vary, depending on the type of tumor (Ehrlich, 2002).
DNA hypomethylation also has a profound impact on expression in various regions of the
genome. The studies done by Gama-Sosa et al. (1983) were some of the first to correlate cancer
and hypomethylation in euchromatin, looking at brain gliomas. The results from this study
concluded that hypomethylation was correlated with cancer presence, as well as tumor
progression. It suggested that global hypomethylation results in the activation of protooncogenes, which will then result in cancer. DNA hypomethylation in cancer cells usually occurs
in heterochromatic regions, where the repetitive sequences have high to moderate repeat copy
numbers. Hypomethylation in heterochromatic regions has been suggested to allow nonhomologous recombination between repetitive sequence domains, resulting in the extensive
chromosomal rearrangements characterizing cancer cells (Ehrlich, 2002). A study by Ting et al.
(2011) revealed some heterochromatin repetitive sequences to be highly transcribed in pancreatic
ductal adenocarcinomas (PDAC) which were not transcribed in normal cells. There were high
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transcript reads of satellite II and -satellite in cancer cells while there were high transcript reads
of gamma satellite, beta satellite and telomere-associated repeat 1 (TAR1) in normal cells. This
work found that various satellites were activated in a variety of cancers while other satellites
were activated in normal cells. Changes in DNA methylation levels appeared to be involved in
these transcription differences. Thus, studying DNA methylation of different repetitive elements
in the heterochromatic regions will contribute to the overall understanding of their roles in
cancer.
Prostate Cancer
Prostate cancer is one of the major diseases affecting Western men (Jemal et al., 2005)
There are many factors that influence the choice of effective treatment including differences in
symptoms and reproducible molecular markers. Hence the continued development of reliable
biomarkers remains important to treatment. For advanced stages of prostate cancer, the lack of
androgen receptor (AR) expression was identified to be a major contributing factor to
tumorigenesis (Hobisch et al., 1995). Jarrard et al. (1998) found that aberrant methylation at the
5’ end of the AR gene correlated with the loss of AR expression in prostate cancer.
Hypermethylation of the promoter region resulted in no androgen receptor expression, and
progressive tumorigenesis. However, when the AR negative cells were treated with the
demethylating agent 5-aza-2’deoxycytidine there was a reintroduction of AR expression in the
cells, except for in the most aggressive prostate cancer cell line DU145 (Jarrard et al., 1998).
Many other genes also undergo methylation changes, including hypermethylation of the
glutathione-S-transferase-p1 (GSTP1) gene which is the most common characteristic of prostate
cancer. The GSTP1 gene is associated with tumor suppression activity (Zhang et al., 2015). It is
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suggested that GSTP1 becomes hypermethylated due to the aberrant proliferation in prostate
cancer cells (Schulz and Hatina, 2006).
While the focus of methylation studies relating to prostate cancer primarily have looked
at euchromatin, recently more studies have emphasized the correlation of prostate cancer and
methylation changes in repetitive sequences in heterochromatin (Criscione et al., 2014). Many
studies have indicated that LINE-1s retrotransposons are hypomethylated in cancer (Ehlrich et
al., 2006, Weisenberger et al., 2005). In prostate cancer, LINE-1 has also been found to be
hypomethylated and overexpressed (Santourlidis et al., 1999). Barry et al. (2015) demonstrated
that methylation of LINE-1 in peripheral blood did not have any correlation with prostate cancer
risk, but Alu elements do. They found that an increased level of methylation in Alu elements is
significantly correlated with prostate cancer risk.
Human Chromosome 21p (HC21p)
The short arm of HC21 is the ideal model for studying the structure and function of
heterochromatin. HC21 is the smallest chromosome in the genome, containing about 1-1.5% of
the human genome (Hattori et al., 2000). The short (p) arm of the chromosome is primarily
heterochromatin and its physical map has been well-characterized (Doering et al., 1993). The
short arm of HC21 is devoid of genes, except for the localized rDNA (Henderson et al., 1999),
and is primarily composed of large clusters of tandem repeats that are interrupted by “islands” of
low copy number repeats (Fig. 1). The various repetitive DNA families found on HC21p include
LINES, SINES, α-satellite, β-satellites, -satellite, satellites I and III, and several macrosallites
(Doering et al., 1993). This current work examines the DNA methylation patterns in three
repetitive DNA sequences found on HC21: gamma satellite, NBL2 and satellite I subfamilies
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Gamma Satellite
Gamma satellite is one of many satellite sequences that are present in the pericentromeric
regions (Lee et al., 2000) (Fig. 3). It is a tandem array that contains 220bp GC-rich repeating
units that can form 10-200 kb clusters (Lin et al., 1993). Each individual repeat differs from the
others significantly, having only about 60% sequence identity (Kim et al., 2009). Gamma
satellite has been identified in the pericentromeric regions of virtually all chromosomes, but it is
found primarily on chromosomes 8, X, and Y (Lee et al., 2000; Kim et al., 2009). On HC21,
gamma satellite is composed of 15 220bp-repeating units, constituting a 3kb cluster (Fig. 4). It is
located in the pericentromeric region of the long arm, approximately 1Mb from the centromere
(Kim et al. 2009). Pericentromeric regions have normal histones as opposed to centromeres,
which have CENP-A to keep that region of the chromosome in a closed chromatin conformation
(Kim et al., 2009). These pericentromeric regions stabilize the centromeric structure, thus
regulating adjacent gene expression. Kim et al. (2009) confirmed that gamma satellite has an
antisilencing activity, which gives it the ability to act as a barrier, preventing heterochromatic
silencing of the centromere from spreading into the long arm. Although gamma satellite is
located in the pericentromeric region, it contains H3K4me2 and H3K9me3 euchromatic
chromatin modifications suggesting an open chromatin configuration (Kim et al., 2009). Ting et
al. observed a decrease in transcription of gamma satellite on the X chromosome in pancreatic
ductal adenocarcinoma (Fig. 2) relative to normal cells. Based on these results, it would be
predicted that gamma satellite is hypermethylated in the cancer cells.
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NBL2 Repeat
NBL2 is a 60% G/C rich tandem repeat that is 1.4 kb long. Its high G/C content is similar
to CpG islands of promoters, though it is much longer (Takai and Jones, 2002; Nishiyama et al.,
2005). NBL2 is present on chromosomes 9, 13, 14, 15, 21, and Y (Fig. 5) and most clusters
appear to be located in centromeric regions rather than acrocentric short arms (Thoraval et al.,
1996; Nishiyama et al., 2005). Very little NBL2 sequence data exists and its detailed map
locations in the genome are unclear. Nishiyama et al. (2005) have mapped NBL2 repeats on a
BAC from an unknown chromosome that contained 20 1.4kb tandem repeats (Fig. 6).
Many studies have demonstrated altered methylation levels in NBL2 in a variety of
diseases. NBL2’s normal methylation level is dependent upon DNMT3B (Kondo et al., 2000). A
positive correlation was observed between methylation in NBL2 and inhalation of silicon and
calcium (Hou et al., 2014). It was proposed that particulate matter like Si and Ca induces a
change in NBL2 methylation, leading to carcinogenesis. A follow up study looking at the
differences in NBL2 methylation between truck drivers, who are more exposed to particulate
matter, and office workers resulted in no significant difference between the two (Guo et al.,
2014). Although Si and Ca do not affect office workers methylation status, it is instead affected
by S exposure, resulting in changes in -satellite methylation (Guo el al., 2014).
Unlike other satellite sequences that are predicted to be hypomethylated in cancer cells,
NBL2 can either be hypomethylated or hypermethylated depending on the type of cancer
(Nishiyama et al., 2005) (Fig. 7). NBL2 methylation patterns appear to be tumor-specific
(Costello et al., 2000). It was observed by Nishiyama et al (2005b) that the methylation profile
of CpGs of NBL2 differ extensively among tumor types. While some tumors may have low
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levels of methylation others may be completely methylated. For example, NBL2 is
hypomethylated in neuroblastomas, hepatocellular carcinomas, bladder carcinomas and in ICF
syndrome cells while it is hypermethylated in leukemia, ovarian carcinomas, and Wilms tumor
(Choi et al., 2009, Nishiyama et al., 2005). Thus, it was proposed by Nishiyama et al. (2005) that
both hypomethylation and hypermethylation share a common step during tumorigenesis. This
methylation data only represents a few regions within the genome since they used methylation
sensitive restriction enzymes (Nishiyama et al., 2005). While Nishiyama was only able to look at
a few CpG sites, the current study will look at about 30 CpG sites per locus. This is possible
because bisulfite-sequencing PCR will be used. The larger number of CpG sites we will use for
methylation analysis will give a better representation of the methylation status of the entire
tandem array.
Satellite I
Satellite I has a basic A/T rich 42 bp repeat. Each repeat contains two RsaI sites that
cleave the repeats into subunits of 17 and 25bp. These subunits are tandemly organized in an AB-A-B manner, and form clusters hundreds of kb long (Prosser et al., 1986). Satellite I has two
subfamilies on HC21p. The pTRI-6 satellite I subfamily is located at the proximal end of the
short arm of HC21p while Sat I (U05290) is located at the distal end (Kalitsis et al., 1993).
pTRI6 is a 3.0 kp higher order repeat composed of the basic 42bp monomeric repeats. Kalitsis et
al. (1993) demonstrated that pTRI-6 is found on the pericentromeric regions of chromosomes 3
and 4 while it can be detected in both the pericentromeric regions and distal p13 on acrocentric
chromosomes’ short arm. pTRI-6 is predominantly present on chromosome 13, but it is also
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present on chromosome 21 in smaller amounts. There is currently no DNA methylation data
available on these subfamilies.
Research Goals
The goal of this study is to examine the DNA methylation patterns in gamma satellite,
NBL2, and satellite I from HC21p in prostate cancer cell lines that can possibly be used as
biomarkers to detect the early changes associated with cancer. Bisulfite sequencing PCR will be
the method used in this study as it allows for the analysis of many CpG sites at once. Four
different prostate cancer cell lines representing tumors of varying severity will be used in these
studies.

Figure 1. Map of HCp21. This map represents the cluster organization of repetitive sequence
families on HC21p. The proximal cluster of Satellite I (BAC JX174276.1) is located near the
centromere, represented by the yellow box located on the right. The distal cluster of Satellite I
(BAC L2HS6439) is represented by the yellow box near the telomere on the left. Each colored
boxes represent a repetitive family. Figure adapted from Doering et al., 1993.
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Figure 2. A graphical representation of RNA expression in normal cells vs. PDAC cells in
different repetitive families. The black bar represents expression in cancer cells and the white bar
represents expression in normal cells. Gamma satellite (GSAT) appears to be more expressed in
normal cells than cancer cells. Adapted from Ting et al. (2011).

Figure 3. Location of Gamma satellite on HC21. Gamma is located in the pericentromeric region
of the long arm on HC21 at q11.2. Figure obtained from UCSC Genome Browser, Blat tool.

Figure 4. Location of the 3 Gamma satellite primer sets in HC21. Figure obtained from Geneious. Sequence obtained from RepBase.
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Figure 5. The presence of NBL2 on different human chromosomes. NBL2 PCR products using
SCH DNA panel diagramed an in silicio search for the NBL2 array on the BAC (AC018692).
There is a strong presence of NBL2 on HC13, 14, 15, 21, with a less intense presence on HC 9
and Y. Figure adapted from Nishiyama et al. 2005.

F11-R11 (0.62kb)

F9-R9 (0.48kb)
F12-R9 (1.16kb)

F6-R8 (0.40kb)
F2-R1 (0.85kb)

F8-R17 (1.00kb)

Figure 6. Location of different primer sets from Nishiyama’s study in BAC AC018692. There were 6 different primers used. 5 of the
primers contain a primer located within the NBL2 repeat and the other primer is located in a unique region that is adjacent to NBL2.
Primers position in the NBL2 adjacent sequence include: F9, F11, R11, F12, R8, and R17. Primers position within the NBL2 array
include: F2, R1, R9, F6, and F8. Figure adapted from Nishiyama et al. (2005).
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Figure 7. Association of NBL2 Methylation changes to Ovarian and Wilms tumor Malignancy.
Methylation changes in cystadenomas, LMP, carcinomas derived from ovarian tumors, and
Wilms tumor at NBL2 HhaI sites displayed hypermethylation relative to the normal standard,
with some hypomethylation in the carcinomas. The hypermethylation at NBL2 HhaI sites in
association with tumor malignancy was significantly different for ovarian tumors, but not in
Wilms tumors. Figure adapted from Nishiyama et al. (2005).

CHAPTER TWO
MATERIAL AND METHODS
DNA from Cell Lines and Tissues
A total of 7 different DNA templates were used for this project. DNA from the HC21containing hybrid cell line WAV-17 was obtained from Coriell Cell Repositories. Genomic
DNAs from human peripheral blood leukocytes and human placenta were obtained from
Biochain. DNAs from 4 different prostate cancer cell lines were used, which all differed in the
state of tumor progression. RWPE-1 is a normal human prostate line that has been transformed
with HPV (Bello et al., 1997). LNCaP is the least aggressive prostate cancer cell line of the three
malignant cell lines because it is isolated from metastatic lymph nodes and it is androgensensitive (Horoszewicz et al., 1983). PC-3 is the second most aggressive prostate cell line, and
was isolated from lumbar metastasis and it is androgen-insensitive, resulting in its aggression
(Tai et al., 2011). Similar to PC-3, DU145 is also androgen-insensitive. DU145 is the most
aggressive prostate cancer line due to its brain metastasis source (Nemeth et al., 1999). Dr.
Jennifer Doll provided DNAs from all 4 of these prostate cancer lines, or it was obtained from
the American Type Culture Collection (ATCC).
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Primer design
Gamma
Primers were designed using the 21q BAC clone CH17-28L5 from chromosome 21 (accession
number AC256301.1), which contains the gamma satellite cluster. The whole BAC sequence
was imported into the Geneious sequence editing program. A common gamma satellite repeat
was found in Repbase (Lin et al., 1993) and the 220bp gamma satellite repeat was used as an
annotation in Geneious, which identified 15 gamma satellite repeats in the cluster. The
OligoAnalyzer program (https://www.idtdna.com/calc/analyzer) was used to design the forward
and reverse primers that meet the criteria optimized for bisulfite sequencing. The criteria for the
primers include having about 50% GC content, a hairpin value less than -5, and a delta value for
the homo dimer and heterodimer of less than 20% of the overall delta value. To make the primers
specific to a particular location, all of the gamma repeats were aligned to look for the few
mismatches. The location of the mismatches between each gamma repeat was used as a primer
site. The Bioinformatics-reverse complement program
(http://www.bioinformatics.org/sms/rev_comp.html) was used to reverse complement a
designated sequence to be used for the reverse primer. After determining the potential primers
using those two programs, the forward and reverse primers were converted using the Bisulfite
Primer Seeker program (http://www.zymoresearch.com/tools/bisulfite-primer-seeker). In
converted primer sets, the forward primer did not contain any cytosine while the reverse primer
did not contain any guanine.
Three separate primers sets were designed for the gamma satellite cluster, and each
primer set includes both the unconverted and converted versions (Fig. 4). The converted primer
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sets are to be used for bisulfite treated samples. The forward primer for the first primer set,
F1R1, lies outside of the gamma region while the reverse primer lies within a gamma repeat (Fig.
4) . The second primer set, F3R3, contains several gamma repeats. The third primer set, F2R2, is
designed similarly to the first primer set but the forward primer lies within the gamma repeat
while the reverse primer lies outside of the gamma repeat. For each set the primers were made
specific for a particular location within the HC21 gamma cluster, as described above. After all of
the primers were created, they were blasted (Primer Blast)
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/) against the genome to ensure that they are
specific to HC21. The results showed only perfect matches on HC21. Imperfect matches on other
chromosomes contained mismatches in the 3’ end of the primer, which would prevent PCR
amplification.
NBL2
The NBL2 array in BAC clone AC0128692 (Nishiyama et al., 2005) was used to design
primers. There are 20 NBL2 repeats in this clone (Fig. 8). The 3 sets of NBL2 primers were
designed in the same way as gamma satellite. They were tested using Primer Blast to ensure their
specificity to HC21. The results showed imperfect matches to other chromosomes, but HC21
showed the best match with 97-99% identity. (Table 2, Fig. 7)
Satellite I
Two different satellite I primers sets were designed. One is located in the proximal
portion of HC21p while the other one is located at the distal end. The proximal satellite I primers
were designed off of HC21p BAC clone JX174276.1 while the distal end used HC21p BAC
clone L2HS6439 with accession number U05290.1 (Fig. 1). These two sequences are relatively
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short, with JX174276.1 being 4,778bps long and U05290.1 being 596bps. Since these two
regions are very similar, they were aligned to determine where the mismatches lie. The location
of the mismatches found from the BLAST results was used to create specific primers. The
parameters for designing the primers were the same as for gamma and NBL2. Once the primers
were designed, they were tested using primer blast to determine that the primers would only bind
to the sequence it was designed from and not the other sequence. The result from primer blast
showed specificity to its own sequence and HC21. (Table 2)
Primer testing
To determine if the converted primers could amplify bisulfite treated DNA, PCR
reactions were run with EpiTect PCR Human Control (QIAGEN) DNA. The control DNA used
was bisulfite converted, and completely methylated. This was a positive control, which
determined if the converted primer sets would amplify the amplicon of interest. The PCR
products were then run on 1% agarose gels to verify the expected amplicon size. Temperature
gradients were used to optimize the amplification. Usually a lower temperature, relative to the
ideal temperature shown in OlgioAnalyzer, was used. (Figs. 9-16)
Bisulfite conversion
The QIAGEN Epitect Plus Bisulfite Kit was used for the bisulfite conversion process,
with 1g of input DNA in each reaction. The conversion process was followed exactly as stated
in the protocol with one modification. At the final step, the DNA was eluted for 15 minutes
instead of 1 minute. The results obtained routinely showed > 95% efficiency conversion.
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PCR
Amplification conditions for unconverted NBL2 primers were 95˚C for 15 min; 35 cycles
of 95˚C for 15 sec, 52-59˚C for 15 sec, 72˚C for 30 sec; and then 72˚C for 5 min (Nishiyama et
al., 2005). Conditions for Pyromark (QIAGEN): 95˚C for 15 min; 45 cycles of 94˚C for 30 sec,
annealing temps for 30sec, 72˚C for 30 sec; and then 72˚C for 10 min. Each reaction contained
12.5 l of Pyromark, 0.5 l of the forward primer and 0.5 l of the reverse primer (0.2 M each),
and variable water and DNA volumes to a final volume of 25 l. The final DNA input for the
PCR reaction used for unconverted primers was 200 ng and for the converted primers it was 10
ng in the first round.
Conditions for Epik (Bioline); 95˚C for 2 min; 30 cycles of 95˚C for 15 sec, annealing
temps for 15 sec, 72˚C for 30 sec. Each reaction contained 25 l of Epik, 1 l of the forward
primer and 1 l of the reverse primer (25 M each), and variable water and DNA volumes to a
final volume of 50 l. The Pyromark and Epik polymerase kits were used for both bisulfitetreated and untreated samples. Pyromark was the kit primarily used for all the primer sets since it
produced the most successful amplification. However, Epik was used for the gamma F3R3
primer set. Unconverted primers were run for one round while the converted primers usually
required two PCR rounds. The PCR product from the first round was diluted over a range (1:100,
1:50, and 1:25) and only 1 l of this PCR dilution was added to the second PCR reaction.
Hybrid cell line mapping
An HC21 hybrid cell-mapping panel was used to determine the location of NBL2 on
HC21p. Unconverted NBL2 primers that were used are F1R2, F6R8 and F9R9 (Nishiyama et
al.2005) (Fig. 6). The cell lines used were ACEM, X21, 21X, R21, E7BX, 2FUR1, and WAV-17
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(Graw et al., 1995). WAV-17 is the control since it contains the whole HC21. Each cell line
contains a different fragment of the short arm (Fig. 17). The products of each PCR reaction were
next to each other on 1% agarose electrophoretic gels. A band will show up if the NBL2
sequence is located on that fragment of HC21, allowing the determination of the NBL2 sequence
location on the short arm.
Cloning and transformation
The cloning process was performed according to the TOPO TA Cloning Kit (Invitrogen)
but room temperature incubation was for 45 minutes instead of 5 in minutes. Transformation was
performed with 6 l of the cloning reaction using the Zymo Premade Mix & Go Competent E.
coli Cells exactly as specified by the manufacturer. The cells were spread on LB Ampicillin
plates and incubated overnight at 37C. The colonies were picked and restreaked and then
incubated overnight at 37C. A minimum of 24 colonies were picked for each sample.
Minipreps
The Zymo Zyppy Plasmid Miniprep Kit protocol was used exactly as specified by the
manufacturer. The QIAprep Miniprep was used with few modifications. At step 4 of the
protocol, instead of centrifuging the flip-top tube for 10 minutes at maximum speed, it was spun
for 15 minutes. Also for the last step, instead of eluting water for 1 minute, it was eluted for 15
minutes; spun down with the centrifuge for 1 minute; re-eluted for another 15 minutes; and then
spun down with the centrifuge for 1 minute. The MidSci IBI High Speed Plasmid Miniprep Kit
was used exactly as indicated in the protocol, but the EB buffer was replaced with autoclaved,
distilled water to elute. Purified DNA was sent to ACGT, Inc or GeneWiz for sequencing.
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Programs for sequence analysis
Geneious
Geneious was used for sequence analysis. A primer folder was created in the program,
containing all the different unconverted and converted primers. Raw sequence data were
imported into the program and they were annotated using the primers. Sequences outside the
forward and reverse primers were cut out. Then the forward and reverse strands of a clone were
aligned together to generate a consensus for the clone. This process was repeated for the other
clones. After all the clones were annotated, they were aligned to create the master consensus. A
FASTA document containing all of the converted clones was created to be use for QUMA. The
converted clones need a FASTA document containing all of the clones while the unconverted
sequence only needed the master consensus.
QUMA
This program (http://quma.cdb.riken.jp/) is Quantification tool for Methylation Analysis
(QUMA). It gives the methylation statistics of each clone and the overall percent methylation. It
also gives a diagrammatic representation of the methylation. The unconverted master consensus
and the converted clones FASTA document were uploaded onto the program. The percent
conversion efficiency was set to 95% to exclude clones that fall below this. The strict CpG site
check of bisulfite sequence for repetitive sequence option in the program was selected, which
accounts for the potential polymorphisms at CpG sites that can result from amplifications in
different regions of the genome. After the submission, the statistics for the sequence with the
specific DNA template was generated, along with a picture. The statistics include the number of
CpG sites, the percent methylation of each CpG sites across all clones, and the overall
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methylation. The picture representation of the statistics contains open and closed circles. The
open circles mean that the CpG sites are unmethylated while the closed circles means that they
are methylated (Fig. 21).

Figure 8. Location of 3 NBL2 primer sets using BAC AC018692. There is a total of 20 NBL2 repeats present on this BAC, which
comes from an unknown chromosome. Primers located in the adjacent sequence include: NBL2 F1.2 and NBL2 R3. Primers located in
the adjacent NBL2 sequence include: NBL2 R1.2 and NBL2 F3. Both the forward and reverse primers in locus 2 (NBL2 F2R2)
are located within the NBL2 repeat. Figure obtained from Geneious.
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694bps

Figure 9. Converted Gamma F1R1 PCR on Converted Human Control DNA 1% agarose gel.
The ideal annealing temperature for this locus was determined by the temperature gradient
(Table 3). PCR product was obtained through 2 rounds of amplifications.

401bps

Figure 10. Converted Gamma F2R2 PCR on Converted Human Control DNA 1% agarose gel.
The ideal annealing temperature for this locus was determined by the temperature gradient
(Table 3). PCR product was obtained through 1 round of amplification.
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728bps

Figure 11. Converted Gamma F3R3 PCR on Converted Human Control DNA 1% agarose gel.
The ideal annealing temperature for this locus was determined by the temperature gradient
(Table 3). PCR product was obtained through 2 rounds of amplifications.

705bps

Figure 12. Converted NBL2 F1R1 PCR on Converted Human Control DNA 1% agarose gel. The
ideal annealing temperature for this locus was determined by the temperature gradient (Table 3).
PCR product was obtained through 2 rounds of amplification.
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775bps

Figure 13. Converted NBL2 F2R2 PCR on Converted Human Control DNA 1% agarose gel. The
ideal annealing temperature for this locus was determined by the temperature gradient (Table 3).
PCR product was obtained through 2 rounds of amplifications.

709bps

Figure 14. Converted NBL2 F3R3 PCR on Converted Human Control DNA 1% agarose gel. The
ideal annealing temperature for this locus was determined by the temperature gradient (Table 3).
PCR product was obtained using 2 rounds of amplifications.
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~250bps

Figure 15. Converted Distal Sat. I Distal PCR on Converted Human Control DNA 1% agarose
gel. The ideal annealing temperature for this locus was determined by the temperature gradient
(Table 3). Expected size is 379pbs, but amplification is around 250bps. PCR products obtained
through 2 rounds of amplifications.
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Figure 16. Converted Proximal Sat. I PCR on Converted Human Control DNA 1% agarose gel.
The ideal annealing temperature for this locus was determined by the temperature gradient
(Table 3). There was no amplification through 2 rounds of amplifcations. Expected size is
714bps.
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p arm

rDNA
Centromere

par
____
_
____
_
q arm 2FUR1 R21

E7BX 21X, X21

ACEM

E9A

Figure 17. HC21 Hybrid Cell Map. Each cell line fragment contains a portion of HC21. By
detecting the present of the particular amplicon with a specific hybrid cell line, the approximate
location of the amplicon on the p-arm of HC21 is determined. Image adapted from Doering et
al. (2007).

GAMMA

Figure 21. Methylation of Gamma F1R1 in WAV-17. Open circles: Unmethylated CpGs; Closed circles: Methylated CpGs. Top
numbers represent CpG numbers while the bottom numbers are the position of the CpG within the amplicon. CpGs located within
Gamma sequence starts after the 2nd CpG. Each line represents one clone. The bottom figure shows the average methylation at each
CpG site of this locus.
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GAMMA SATELLITE
AAA GGT GAG CCA ATG GGG TAC AAA A
TTT TCC CTG GAA TGC CTC AAC ATC C
AAA GGT GAG TTA ATG GGG TAT AAA A
TTT TCC CTA AAA TAC CTC AAC ATC C
GGC ATC CTG TTA CCT TTC TCT GGG GGA A
AAG GAC ATT GCC TTT GCC AGC TAC CAG G
GGT ATT TTG TTA TTT TTT TTT GGG GGA A
AAA AAC ATT ACC TTT ACC AAC TAC CAA A
AAA ACA GTG CCT GCC AGC AGA CCC TGG G
GGG CTT TCT TGC AGC TTT GGG GTG CCA CC
AAA ATA GTG TTT GTT AGT AGA TTT TGG G
AAA CTT TCT TAC AAC TTT AAA ATA CCA CC

*

NBL2
ACT GCT GTC ATC AGG AGA GGT TCC CTT

NBL2 11
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*
G. F1
G. R1
G. CON F1
G. CON R1
G. F2
G. R2
G. CON F2
G. CON R2
G. F3
G. R3
G. CON F3
G. CON R3

*

SATELLITE 1 SUBFAMILIES

DISTAL F

GCA GTA TAT AAT ATA TAG TTT GAG AAC TT

DISTAL R

ACA TAA GAT AGG AAA TTA CAT CAA TAT AT

DISTAL CON F

GTA GTA TAT AAT ATA TAG TTT GAG AAT TT

DISTAL CON R

ACA TAA AAT AAA AAA TTA CAT CAA TAT AT

PROX F

GCA TAA AAT ATG AAG GTA CAT CAA AT

PROX R

ATG GAC AGT ATA TAA TAC ACA GTT TG

PROX CON F

GTA TAA AAT ATG AAG GTA TAT TAA AT

PROX CON R

ATA AAC AAT ATA TAA TAC ACA ATT TA

*

NBL2 (Nishiyama et al., 2005)

F2

GTT TGT ACC AGC CGA AGT TGC

R1

TCC ACT CCT GAC AGA TAG GCT G

F6

GTC GTT CTC CTC CAG AGC AGA

NBL2 R1

TCC TCT TTG CAG TTG TCC TGT AAA GCA TGG

NBL2 CON F1

ATT GTT GTT ATT AGG AGA GGT TTT TTT

NBL2 CON R1

TCC TCT TTA CAA TTA TCC TAT AAA ACA TAA

NBL2 F2

GGG ATG CAG CCT ATC TGT CAT TAG TGG AG

R8

GAT GAG ATT TCA CTT GCT CCG

NBL2 R2

GCC AAA GGA AAA TCA AAC AAC ACC TGG G

F8

GAT GAC AGC AGT CGC AAA G

NBL2 CON F2

GGG ATG TAG TTT ATT TGT TAT TAG TGG AG

R17

CAT CTT TGT TGA AGG CAT TCG G

NBL2 CON R2

ACC AAA AAA AAA TCA AAC AAC ACC TAA A

F9

CCT TAC TAG CTT CTG TGG GCA

NBL2 F3

AGT CAT AGA GCA GAG GCA TTG AAA CAC ACA

NBL2 F3

GTG AAC ACA GCA GGC ATC CTG AAG TT

R9

TGA GTG AGA TAG GAT GGG CTC

F12

GCT AAG GCT GTG GTG GGA AA

NBL2 CON F3
NBL2 CON R3

AGT TAT AGA GTA GAG GTA TTG AAA TAT ATA
ATA AAC ACA ACA AAC ATC CTA AAA TT

F11

GAG TAA ACT GAA AGC AGG CAGA

Table 2. Primer Sequences. Primers used for the sequence families studied in this project. F indicates forward; R indicates reverse; con
indicates converted primers. Others unconverted. Listed 5’ to 3’.
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CHAPTER THREE
RESULTS
Analysis of NBL2 Sequence on Chromosome 21
Nishiyama et al. (2005) designed six primer sets for NBL2 from BAC AC018692 (Fig.
6). These six primer sets were used in PCR reactions (Table 3) on WAV-17 DNA to confirm that
these NBL2 sequences were present on HC21 (Fig. 18-20). The PCR fragments obtained were
cloned and sequenced and a consensus sequence was created for each primer set (Fig. 8). Then
the consensus sequence for each PCR product was blasted against the BAC AC018692 to
determine the sequence similarity of the consensus sequence to the original BAC. Each PCR
product had high sequence similarity to the original BAC (Fig. 7). The beginning region had a
99%, the middle region had 96%, and the ending region had 98% similarity. This result
confirmed that the amplicons from the six primer sets do exist on HC21, however the lack of
complete identity leaves open the possibility that the original NBL2 BAC does not originate
from HC21.
Hybrid Cell Line Mapping of NBL2 on Chromosome 21
A panel of hybrid cell lines were used to define the location of NBL2 on HC21.
Although there are six sets of primers, some of them overlapped so only a total of three different
primer sets were used. The three different primer sets include F9R9, F2R1, and F6R8 (Fig. 6).
These primer sets cover the beginning, middle and end of the NBL2 repeat array (Fig. 6). F9R9
is the primer set that covers the beginning of the NBL2 tandem repeat array, forming a 480bp
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amplicon. This PCR product was found to be present in ACEM, 21X, E7BX, and WAV-17
(Figure 18). A larger amplicon of 760bp was also observed in E7BX in addition to the 480bp
fragment. This larger amplicon was also seen in 2FUR1. When using the hybrid cell lines, there
can be additional PCR products coming from other chromosome contaminants. Using the HC21
hybrid cell map (Figure 17) as a guide to interpreting these PCR results, one can conclude that
the F9R9 480bp amplicon is present between the E7BX and R21 breakpoints indicating its
pericentromeric location. This is in agreement with Nishiyama’s finding (Nishiyama et al.,
2005).
F2R1 is the primer set that is in the middle of the NBL2 tandem repeat array and gives an
847bp amplicon (Fig.19). Of the seven different hybrid cell lines used, F2R1 was only found to
be present in 21X, E7BX, and WAV-17 (Fig. 17, 19). Thus F2R1 was found to be located
between E7BX and R21 breakpoints near the centromere, the same location as the F9R9
amplicon.
F6R8 is the primer set that is located at the ending portion of the NBL2 array, and its
amplicon is 400 bp (Fig. 6). When mapped using the hybrid cell lines, the F6R8 product was
found to be present in the following hybrid cell lines: ACEM, 21X, E7BX, and WAV-17 (Figure
20). There was a PCR product slightly smaller than 400bp in the 2FUR1 cell line, which was not
used in the mapping. F6R8 was found to be between E7BX and R21. Thus, all three primer sets
map NBL2 to the pericentromeric p-arm of HC21.
NBL2 primer mapping via Genome Browser
The use of hybrid cell lines provided the relative location of the NBL2 tandem repeat
array on the p-arm of HC21. The Genome Browser Blat Tool was used to determine the
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coordinates for the NBL2 amplicons more precisely. Three main primer sets were used since
some of the primer sets overlap each other (Fig. 6). F8R17 is the amplicon that covers the
beginning portion of the NBL2 tandem array, including some adjacent sequence. Its coordinates
on HC21p are 9810121-9811127, with a 98.8% sequence identity to the original BAC (Table 1).
Within the F8R17 amplicon is the F6R8 primer set. F6R8 coordinates on HC21p are 98105309810933, with a 99.6% similarity (Table 1). F2R1 is the primer set that covers only the NBL2
repeat. It has a coordinate of 9822594-9823440 on HC21p, with a 98.1% similarity (Table 1).
F12R9 is the amplicon that covers the ending region of the NBL2 repeat, including some
adjacent sequence. On HC21p, its coordinates are 9839764-9840913, with a 99.4% similarity
(Table 1). The F12R9 amplicon encompasses two other primer sets including F11R11 and F9R9.
F11R11 has a coordinate of 9840251-9840801 on HC21p, with a 99.3% similarity (Table 1).
F9R9 has a coordinate of 9839764-9840239, with a 99.4% similarity. These results indicate that
the NBL2 cluster on HC21p is more than 1Mb from the centromere (Ziccardi et al., 2016) and
not as pericentromeric as Nishiyama assumed. The overlap between the NBL2 BAC clone
AC018692 and the HC21p genomic clone CR382285.2 confirms that NBL2 is farther from the
centromere than previously thought.
Analysis of Satellite I
Methylation analysis could not be performed for the two satellite I sequences because the
results from the control test were negative. For the distal satellite I amplicon, the control test
showed an amplicon fragment around 250bp (Fig. 15). However, the actual size for this primer
set is supposed to be 379bp. After repeating the amplification process a number of times, trying
different PCR annealing temperatures (Table 3), the same 250bp fragment continued to result.
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Since the expected amplicon was not seen, this distal satellite I amplicon was not used. For the
proximal satellite I amplicon, no amplification was observed. Even trying various annealing
temperatures, no PCR fragments were obtained so this primer set was not used.
Methylation Analysis of Gamma Loci
Bisulfite sequencing PCR (BSP) was utilized to study the methylation patterns of the
gamma satellite locus on HC21. Three primer sets, designed as described in the Methods section,
were used in this analysis. The F1R1 primer set covers the beginning of the gamma satellite
tandem repeat array. The F2R2 primer set covers the ending region of the array, while F3R3
covers the middle portion of the array (Fig. 3). The specifics for each primer set are in Tables 1,
2, and 3.
All three of the primer sets were tested on the control DNA and all produced PCR
fragments of the expected amplicon sizes (Fig. 9-11). For each primer set, the first cell line used
in BSP was WAV-17. This cell line is a HC21 hybrid cell line that contains only one copy of
chromosome 21, and it thus contains a single allele of each locus (Lyle et al., 2007). WAV-17 is
used as a control because it confirms the presence of the loci on HC21 and shows any variations
in methylation within a single sample. Methylation data from this template does not necessarily
represent the actual methylation patterns of normal human tissues, and so methylation data from
normal peripheral leucocytes and placenta were also collected. In addition to these two normal
tissues, DNAs from four different prostate cell lines of varying degrees of severity were used for
the study.
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Analysis F1R1 with WAV-17
After BSP and sequencing, the F1R1 amplicon was analyzed on QUMA to determine the
methylation patterns in WAV-17 (Fig. 3). The F1R1 amplicon is 694bp and contains a unique
adjacent sequence region at the beginning of the amplicon, while the rest is in the Gamma array
(Fig. 9). There are two CpG sites in the adjacent sequence (Fig. 21). This locus had a very high
methylation level, with most clones being 100% methylated all CpG sites (Fig. 21). There were
some unmethylated CpGs at two different sites (Fig. 21). The overall methylation of this
amplicon, including the adjacent sequence is 97.4% (Table 4). The percentage methylation of
just the gamma sequence is 97.2% (Table 4).
Analysis of F1R1 with Human Peripheral Leukocytes (WBC)
The methylation analysis for F1R1 with human peripheral leukocytes (WBC) was carried
out in the same manner as for the template WAV-17. Again, the methylation level for this
template is very high with most clones having 100% methylation at most CpG sites (Fig. 22).
The occasionally unmethylated CpGs occur both at the beginning and end of the sequence (Fig.
22). Including the two CpG sites outside of the gamma tandem repeat array, the total methylation
percentage for this template is 97.3% (Table 4) while the percent methylation of just the gamma
sequence is 97.4% (Table 4).
Analysis of F1R1 with Human Placenta
Placenta is a unique tissue to use for methylation analysis. It is known that during
development, the whole genome is demethylated and then gets remethylated (Okano et al.,
1999). Thus, it was expected that gamma satellite in placenta would be hypomethylated.
However, this was not the case. Two different amplicon lengths were obtained, one being the
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originally designed length of 694 bps while the other amplicon was 445 bps long. This was only
observed when using the converted primers. There was only one amplicon length, the expected
694bp, when using the unconverted primers. For the converted primers, the overlap between the
two amplicons is located at the beginning of the sequence, covering CpG sites positioned at 47440 (Fig. 23, 24). The shorter amplicon contains about 1.5 gamma satellite repeats while the
longer amplicon contains 3 repeats. The overall percent methylation of the longer repeat,
including the adjacent sequence, is 79.9% (Table 5), while for just the gamma sequence it is
78.7% (Table 4). The lower methylation level observed in the long amplicon occurred mostly in
the later region of the sequence, starting at CpG number 19 (Fig. 23). For the shorter repeat, the
overall percent methylation is 92.2% (Table 4) while for just the gamma sequence it is 91.7%
(Table 4). Thus, the shorter amplicon is methylated at high levels similar to that seen in WAV
and WBC while the longer amplicon is distinctly less methylated. While both the longer and
shorter clones overlap the same sequence, there was a slight difference in the methylation level
between the two, from CpG number 1-19. The longer amplicon has more unmethylated CpGs
and it was widespread, whereas the unmethylated CpGs for the shorter amplicon occurs mainly
in just two clones (Fig. 23-24).
Analysis of F1R1 with RWPE-1
RWPE-1 is a transformed normal prostate cell line (see Materials and Methods). The
same two different sized amplicons seen with placenta were obtained for this template. Only 4
clones were obtained for the longer amplicon methylation analysis (Fig. 25), while 8 clones were
obtained for the shorter amplicon (Fig. 26). The overall methylation for the longer amplicon is
65.5% and for the shorter amplicon it is 92.8% (Table 4). The drastic difference between the
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longer amplicon and the shorter amplicon is due to the two clones that are highly unmethylated.
The methylation level of just the gamma sequence for the longer clones is 62.9% and for the
shorter clones it is 91.9% (Table 4). The shorter amplicon had about the same high methylation
levels as WAV, WBC and the short placenta clones, while the longer amplicon here is somewhat
less methylated than that seen in the other samples (Table 4). None of the longer clones were
100% methylated. Two of the longer clones are 22% and 55% methylated while the other two
clones are 85% methylated. The shorter amplicons all have very high methylation levels, with all
clones having only a few unmethylated CpGs at the end of the sequence.
Analysis of F1R1with LNCaP
LNCap is the first prostate cancer cell line used and represents the least aggressive form
of cancer. The same two amplicon sizes were again obtained (Fig. 27). CpG sites at the
beginning of the longer amplicon were fully methylated, while there were unmethylated CpG
sites at the end of the amplicon that occurred in all clones at the same position (Fig. 27). In the
shorter amplicon, nearly all of the CpG sites are methylated, with the exception of a few
unmethylated sites in one clone and one unmethylated site across all clones. The overall
methylation, including the adjacent sequence, for this template is 83.3% for the longer clones
and 88.3% for the shorter clones (Table 4). The percent methylation of just the gamma sequence
is 82.1% for the longer clones and 86.9% for the shorter clones (Table 4).
Analysis of F1R1 with PC-3
PC-3 represents an aggressive form of prostate cancer. The same two amplicon sizes
were again obtained, one was 694bp and the other was 445bp. The longer amplicon is highly
methylated, but there were some CpG sites where a number of clones were unmethylated
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(Fig.29). The shorter amplicon is even more highly methylated, with most sites fully methylated,
while one site is unmethylated across all clones. The overall methylation of this template,
including the adjacent sequence, is 81.9% for the longer amplicon and 93.3% for the shorter
amplicon (Table 4). The methylation level of just the gamma sequence for the longer amplicon is
80.6% and 92.5% for the shorter amplicon (Table 4).
Analysis of F1R1 with DU145
DU-145 represents the most aggressive form of prostate cancer. The same two amplicons
were again obtained for this template. Only one clone was obtained for methylation analysis of
the longer amplicon (Fig. 31). The unmethylated CpGs occurred in the latter half of this
amplicon while the first half of the amplicon was fully methylated. There were 8 clones used for
methylation analysis of the shorter clones (Fig. 32). All of the CpG sites were methylated in the
shorter amplicon, except for an unmethylated CpG at one site across all clones. The overall
percent methylation, including the adjacent sequence, is 83.3% for the longer amplicon and
94.7% for the shorter amplicon (Table 4). The methylation of just the gamma sequence is 82.1%
for the longer amplicon and 94.1% for the shorter amplicon (Table 4).
Analysis of F2R2 with WAV-17
The gamma F2R2 primer set specifies a 401bp amplicon that covers the end region of the
gamma tandem repeat array (Fig. 3). Of the 19 CpG sites found in this amplicon, only the first 17
sites are within the gamma repeat array (Fig 25). The other two CpG sites are located outside of
the gamma repeat, in the unique sequence. There were no unmethylated CpGs in any of the
clones used for methylation analysis (Fig. 25), and thus the overall percent methylation was
100% for both the whole sequence and just the gamma sequence (Table 4).
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Analysis of F2R2 with Human Peripheral Leukocytes
The methylation at this locus was very high, with many of the 12 clones having 100%
methylation (Fig.26). The overall percent methylation including the 2 CpGs outside of the
gamma repeats was 95.1%, while it was 95.0% for just the gamma sequence (Table 4).
Analysis of F2R2 with Human Placenta
Of the 12 clones used for methylation analysis (Fig. 27) four were methylated at all sites.
The other clones had just a few unmethylated sites. The overall percent methylation for this
amplicon was 92.1% for the whole sequence, and it was 92.6% for just the gamma sequence
(Table 4).
Analysis of F2R2 with RWPE-1
Five of the 16 clones used for methylation analysis were methylated at all CpG sites (Fig.
36). The other clones had scattered unmethylated CpG sites, occurring primarily in the latter
portion of the amplicon. The overall percent methylation was 93.1% and it was 93.7% for just
the gamma sequence (Table 4).
Analysis of F2R2 with LNCap
Of the 12 clones used for methylation analysis (Fig. 37), none were methylated at all
CpG sites. The unmethylated CpG sites were scattered throughout the amplicon. The overall
percent methylation was 88.9% for the whole sequence, while the portion containing just the
gamma sequence was 92.5% (Table 4).
Analysis of F2R2 with PC-3
Of the 15 clones used for methylation analysis here, 11 were methylated at all CpG sites.
(Fig. 38). The remaining clones had only one unmethylated CpG site in each clone in no specific
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location. The overall percent methylation is 98.6% for the whole sequence and 98.4% for just the
gamma sequence (Table 4).
Analysis of F2R2 with DU-145
Three of the 12 clones used for methylation analysis were methylated at all CpG sites
(Fig. 39). The other clones had only 1-2 unmethylated sites spread over the amplicon in no
pattern. The overall percent methylation for this template was 94.7% for the whole sequence and
it was 96% for just the gamma sequence (Table 4).
Analysis of F3R3 with WAV-17
Gamma F3R3 is the primer set that specifies a 728bp amplicon in the middle portion of
the tandem array (Fig. 4) so all of the CpG sites analyzed were part of the gamma satellite (Fig.
40). Five of the 8 clones were 100% methylated, while the other 3 clones had 1 or 2
unmethylated CpG sites. The overall percent methylation was 98.5% (Table 4).
Analysis of F3R3 with Human Peripheral Leukocytes (WBC)
This amplicon was especially difficult to work with, being highly repetitive, and it took a
number of PCR reactions to obtain sufficient clones for analyzing this template. There were 12
clones used for methylation analysis (Fig. 41). Three clones were 100% methylated, while the
other clones had 1 or 2 unmethylated CpGs distributed across the amplicon. The overall percent
methylation was 96.5% (Table 4).
Methylation Level Comparisons among Loci
Overall, the gamma satellite loci examined in this study have very high methylation
levels, usually more than 80%. The first gamma satellite locus yielded two different amplicons
for all of the prostate cancer cell lines and placenta. In general, the shorter amplicon tended to be
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more methylated than the longer amplicon. The methylation percentage between the shorter and
longer amplicons across the templates (Table 4) showed a substantial difference, ranging from
5% to 27%. However, the numbers do not take the missing CpG sites into account for the shorter
amplicon in comparison to the longer amplicon. The methylation level calculated for the shorter
amplicon only covers the beginning portion of the entire amplicon, while the longer amplicon
covers the whole PCR product (figs. 23-24). The differences in the observed CpG sites and the
number of clones obtained in the shorter and longer amplicon are what accounts for the
difference in methylation level. Although there was a difference in methylation level between the
two amplicons, both have relatively high methylation with 80% methylation or more. In the
region where both the longer and shorter amplicon overlap, the methylation level between the
two are similar to each other. One exception is with the RWPE-1 template in the longer
amplicon, having only 65.5% methylation. .The second gamma locus examined had similar
methylation status to the first locus across all templates. Both the first and second gamma loci
exhibited slightly lowered methylation for placenta in comparison to other templates. The third
gamma locus also had very high methylation in the templates examined (Table 4).

LOCUS

BAC ACCESSION NUMBER

G. F1R1
G.F2R2
G.F3R3

AC256301.1
AC256301.1
AC256301.1

LOCUS

BAC ACCESSION NUMBER

NBL2 F1R1
NBL2 F2R2
NBL2 F3R3

AC018692
AC018692
AC018692

LOCUS

BAC ACCESSION NUMBER

1 (proximal)
2 (distal)

JX174276.1
U05290.1

LOCUS

BAC ACCESSION NUMBER

NBL2 F2R1
NBL2 F9R9
NBL2 F11R11
NBL2 F12R9
NBL2 F6R8
NBL2 F8R17

AC018692
AC018692
AC018692
AC018692
AC018692
AC018692

GAMMA
GAMMA POSITION WITHIN
BAC
128874-131948
128874-131948
128874-131948
NBL2
NBL2 POSITION WITHIN
BAC
78068-106853
78068-106853
78068-106853
SATELLITE I
SAT. I POSITION WITHIN
BAC
1-4778
1-569
NBL2 (Nishiyama)
NBL2 POSITION WITHIN
BAC
78068-106853
78068-106853
78068-106853
78068-106853
78068-106853
78068-106853

AMPLICON LOCATION
WITHIN BAC
128811-129504
131599-131999
129082-129809

CHROMOSOME LOCATION
14073905-14074598
14071410-14071810
14073600-14074327

AMPLICON LOCATION
WITHIN BAC
78430-79134
87752-88526
106335-107043

CHROMOSOME LOCATION

AMPLICON LOCATION
WITHIN BAC
28-741
190-568

CHROMOSOME LOCATION

AMPLICON LOCATION
WITHIN BAC

CHROMOSOME LOCATION

89908-90754
107078-107557
107565-108115
107078-108227
77844-78247
77441-78441

9822594-9823440
9839764-9840243
9840249-9840801
9839764-9840913
9810530-9810933
9810127-9812534

9811116-9811820
9820438-9821212
9839021-9839729

N/A
N/A

Table 1. Positions of primers for sequences studied. The BAC number and position within the BAC from which the primers were designed
are indicated. The chromosome position within HC21 is listed using Genome Browser on the reference genome (hg38). N/A in the
chromosome location indicates that the sequence could not be located. The position of NBL2 primer set F12R9 encompasses all three
primer sets F9R9, F11R11, and F12R9. The positions of NBL2 primer set F8R17 encompass primer sets F6R8 and F8R17 (Fig. 6).

44

*
G. F1
G. R1
G. CON F1
G. CON R1
G. F2
G. R2
G. CON F2
G. CON R2
G. F3
G. R3
G. CON F3
G. CON R3

GAMMA SATELLITE
AAA GGT GAG CCA ATG GGG TAC AAA A
TTT TCC CTG GAA TGC CTC AAC ATC C
AAA GGT GAG TTA ATG GGG TAT AAA A
TTT TCC CTA AAA TAC CTC AAC ATC C
GGC ATC CTG TTA CCT TTC TCT GGG GGA A
AAG GAC ATT GCC TTT GCC AGC TAC CAG G
GGT ATT TTG TTA TTT TTT TTT GGG GGA A
AAA AAC ATT ACC TTT ACC AAC TAC CAA A
AAA ACA GTG CCT GCC AGC AGA CCC TGG G
GGG CTT TCT TGC AGC TTT GGG GTG CCA CC
AAA ATA GTG TTT GTT AGT AGA TTT TGG G
AAA CTT TCT TAC AAC TTT AAA ATA CCA CC

*

NBL2

NBL2 11

ACT GCT GTC ATC AGG AGA GGT TCC CTT

NBL2 R1

TCC TCT TTG CAG TTG TCC TGT AAA GCA TGG

NBL2 CON F1

ATT GTT GTT ATT AGG AGA GGT TTT TTT

NBL2 CON R1

*

SATELLITE 1 SUBFAMILIES

DISTAL F

GCA GTA TAT AAT ATA TAG TTT GAG AAC TT

DISTAL R

ACA TAA GAT AGG AAA TTA CAT CAA TAT AT

DISTAL CON F

GTA GTA TAT AAT ATA TAG TTT GAG AAT TT

DISTAL CON R

ACA TAA AAT AAA AAA TTA CAT CAA TAT AT

PROX F

GCA TAA AAT ATG AAG GTA CAT CAA AT

PROX R

ATG GAC AGT ATA TAA TAC ACA GTT TG

PROX CON F

GTA TAA AAT ATG AAG GTA TAT TAA AT

PROX CON R

ATA AAC AAT ATA TAA TAC ACA ATT TA
NBL2 (Nishiyama et al., 2005)

F2

GTT TGT ACC AGC CGA AGT TGC

R1

TCC ACT CCT GAC AGA TAG GCT G

TCC TCT TTA CAA TTA TCC TAT AAA ACA TAA

F6

GTC GTT CTC CTC CAG AGC AGA

NBL2 F2

GGG ATG CAG CCT ATC TGT CAT TAG TGG AG

R8

GAT GAG ATT TCA CTT GCT CCG

NBL2 R2

GCC AAA GGA AAA TCA AAC AAC ACC TGG G

F8

GAT GAC AGC AGT CGC AAA G

NBL2 CON F2

GGG ATG TAG TTT ATT TGT TAT TAG TGG AG

NBL2 CON R2

ACC AAA AAA AAA TCA AAC AAC ACC TAA A

R17

CAT CTT TGT TGA AGG CAT TCG G

NBL2 F3

AGT CAT AGA GCA GAG GCA TTG AAA CAC ACA

NBL2 F3
NBL2 CON F3
NBL2 CON R3

GTG AAC ACA GCA GGC ATC CTG AAG TT
AGT TAT AGA GTA GAG GTA TTG AAA TAT ATA
ATA AAC ACA ACA AAC ATC CTA AAA TT

F9
R9

CCT TAC TAG CTT CTG TGG GCA
TGA GTG AGA TAG GAT GGG CTC

F12
F11

GCT AAG GCT GTG GTG GGA AA
GAG TAA ACT GAA AGC AGG CAGA

Table 2. Primer Sequences. Primers used for the sequence families studied in this project. F indicates forward; R indicates reverse; con
indicates converted primers. Others unconverted. Listed 5’ to 3’.
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GAMMA
Locus
G. F1R1
G. F2R2
G. F3R3

Temp Gradient (°C)
(Unconverted/Converted)
56-72/50-55
60-65/52-57
69-74/59-64

Length (bps)

# of CpGs

694
401
728

29
19
34

NBL2
Locus
NBL2 F1R1
NBL2 F2R2
NBL2 F3R3

Temp Gradient (°C)
(Unconverted/Converted)
66-71/49-54
59-64/48-53
61-66/46-56

Length

# of CpGs

705
775
709

39
37
40

SATELLITE 1 SUBFAMILIES
Locus
DISTAL F1R1
PROX F2R2

Temp Gradient (°C)
(Converted)
35-50
35-50

Length

# of CpGs

379
714

4
4

NBL2 (Nishiyama et al., 2005)
Locus
NBL2 F2R1
NBL2 F9R9
NBL2 F11R11
NBL2 F12R9
NBL2 F6R8
NBL2 F8R17

Temp Gradient (°C)
(Unconverted)
54-59
53-58
53-58
54-59
52-59
52-57

Length (bps)

# of CpGs

850
480
620
1160
400
1000

N/A
N/A
N/A
N/A
N/A
N/A

Table 3. Primer information for the different sequences studied. Gamma satellite, NBL2 satellite and Satellite 1 subfamilies with their
corresponding temperature gradients used for PCR, as well as their lengths and number of CpGs within the amplicons.
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1 2 3

5 6

7 8 9

480bps

Figure 18. Unconverted F9R9 PCR with HC21 Hybrid Cell Lines 1% agarose gel. Lane 1:
Ladder; Lane 2: Negative; Lane 3ACEM; Lane 4: X21; Lane 5: 2FUR1; Lane 6: 21X; Lane 7:
R21; Lane 8: E7BX; Lane 9: WAV-17. This NBL2 amplicon is present on the following hybrid
cell lines: ACEM, 21X, E7BX, and WAV-17. It is also present on 2FUR1, but not the right size
amplicon.

1

23

456

78

9

847bps

Figure 19. Unconverted F2R1 PCR with HC21 Hybrid Cell Lines 1% agarose gel. Lane 1:
Ladder; Lane 2: Negative; Lane 3ACEM; Lane 4: X21; Lane 5: 2FUR1; Lane 6: 21X; Lane 7:
R21; Lane 8: E7BX; Lane 9: WAV-17. This NBL2 amplicon is present on the following hybrid
cell lines: 21X, E7BX, and WAV-17.
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1 23 4 56 7

89

400bps

Figure 20. Unconverted F6R8 PCR with HC21 Hybrid Cell Lines 1% agarose gel. Lane 1:
Ladder; Lane 2: Negative; Lane 3ACEM; Lane 4: X21; Lane 5: 2FUR1; Lane 6: 21X; Lane 7:
R21; Lane 8: E7BX; Lane 9: WAV-17. This NBL2 amplicon is present on the following hybrid
cell lines: ACEM, 2FUR1, 21X, E7BX, and WAV-17.

GAMMA

Figure 21. Methylation of Gamma F1R1 in WAV-17. Open circles: Unmethylated CpGs; Closed circles: Methylated CpGs. Top
numbers represent CpG numbers while the bottom numbers are the position of the CpG within the amplicon. CpGs located within
Gamma sequence starts after the 2nd CpG. Each line represents one clone. The bottom figure shows the average methylation at each
CpG site of this locus.
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GAMMA

Figure 22. Methylation of Gamma F1R1 in WBC. Open circles: Unmethylated CpGs; Closed circles: Methylated CpGs. Top numbers
represent CpG numbers while the bottom numbers are the position of the CpG within the amplicon. CpGs located within Gamma
sequence starts after the 2nd CpG. Each line represents one clone. The bottom figure shows the average methylation at each CpG site
of this locus.
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GAMMA

Figure 23. Methylation of Gamma F1R1 in Placenta 694bp long clones. Open circles: Unmethylated CpGs; Closed circles: Methylated
CpGs. Top numbers represent CpG numbers while the bottom numbers are the position of the CpG within the amplicon. CpGs located
within Gamma sequence starts after the 2nd CpG. Each line represents one clone. The bottom figure shows the average methylation at
each CpG site for this locus.
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GAMMA

Figure 24. Methylation of Gamma F1R1 in Placenta 445bp short clones. Open circles: Unmethylated CpGs; Closed circles:
Methylated CpGs. Top numbers represent CpG numbers while the bottom numbers are the position of the CpG within the amplicon.
CpGs located within Gamma sequence starts after the 2nd CpG. Each line represents one clone. The bottom figure shows the average
methylation at each CpG site of this locus.
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GAMMA

Figure 25. Methylation of Gamma F1R1 in RWPE 694bp long clones. Open circles: Unmethylated CpGs; Closed circles: Methylated
CpGs. Top numbers represent CpG numbers while the bottom numbers are the position of the CpG within the amplicon. CpGs located
within Gamma sequence starts after the 2nd CpG. Each line represents one clone. The bottom figure shows the average methylation at
each CpG site of this locus.
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GAMMA

Figure 26. Methylation of Gamma F1R1 in RWPE 445bp short clones. Open circles: Unmethylated CpGs; Closed circles: Methylated
CpGs. Top numbers represent CpG numbers while the bottom numbers are the position of the CpG within the amplicon. CpGs
located within Gamma sequence starts after the 2nd CpG . Each line represents one clone. The bottom figure shows the average
methylation at each CpG site of this locus.
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GAMMA

Figure 27. Methylation of Gamma F1R1 in LNCaP 694bp long clones. Open circles: Unmethylated CpGs; Closed circles: Methylated
CpGs. Top numbers represent CpG numbers while the bottom numbers are the position of the CpG within the amplicon. CpGs located
within Gamma sequence starts after the 2nd CpG. Each line represents one clone. The bottom figure shows the average methylation at
each CpG site of this locus.
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GAMMA

Figure 28. Methylation of Gamma F1R1 in LNCAP 445bp short clones. Open circles: Unmethylated CpGs; Closed circles:
Methylated CpGs. Top numbers represent CpG numbers while the bottom numbers are the position of the CpG within the amplicon
CpGs located within Gamma sequence starts after the 2nd CpG. Each line represents one clone. The bottom figure shows the average
methylation at each CpG site of this locus.
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GAMMA

Figure 29. Methylation of Gamma F1R1 in PC-3 694bp long clones. Open circles: Unmethylated CpGs; Closed circles: Methylated
CpGs. Top numbers represent CpG numbers while the bottom numbers are the position of the CpG within the amplicon. CpGs located
within Gamma sequence starts after the 2nd CpG. Each line represents one clone. The bottom figure shows the average methylation at
each CpG site of this locus.
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GAMMA

Figure 30. Methylation of Gamma F1R1 in PC-3 445bp short clones. Open circles: Unmethylated CpGs; Closed circles: Methylated
CpGs. Top numbers represent CpG numbers while the bottom numbers are the position of the CpG within the amplicon. All sequence
are part of Gamma repeats. Each line represents one clone. The bottom figure shows the average methylation at each CpG site of this
locus.
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GAMMA

Figure 31. Methylation of Gamma F1R1 in DU145 694bp long clone. Open circles: Unmethylated CpGs; Closed circles: Methylated
CpGs. Top numbers represent CpG numbers while the bottom numbers are the position of the CpG within the amplicon. CpGs located
within Gamma sequence starts after the 2nd CpG. Each line represents one clone. The bottom figure shows the average methylation at
each CpG site of this locus.
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GAMMA

Figure 32. Methylation of Gamma F1R1 in DU145 445bp short clones. Open circles: Unmethylated CpGs; Closed circles: Methylated
CpGs. Top numbers represent CpG numbers while the bottom numbers are the position of the CpG within the amplicon. CpGs
located within Gamma sequence starts after the 2nd CpG . Each line represents one clone. The bottom figure shows the average
methylation at each CpG site of this locus.
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GAMMA

Figure 33. Methylation of Gamma F2R2 in WAV-17. Open circles: Unmethylated CpGs; Closed circles: Methylated CpGs. Top
numbers represent CpG numbers while the bottom numbers are the position of the CpG within the amplicon. CpGs located within
Gamma sequence ends after the 2nd CpG. Each line represents one clone. The bottom figure shows the average methylation at each
CpG site of this locus.
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GAMMA

Figure 34. Methylation of Gamma F2R2 in WBC. Open circles: Unmethylated CpGs; Closed circles: Methylated CpGs. Top numbers
represent CpG numbers while the bottom numbers are the position of the CpG within the amplicon. CpGs located within Gamma
sequence ends after the 2nd CpG. Each line represents one clone. The bottom figure shows the average methylation at each CpG site of
this locus.
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GAMMA

Figure 35. Methylation of Gamma F2R2 in Placenta. Open circles: Unmethylated CpGs; Closed circles: Methylated CpGs. Top
numbers represent CpG numbers while the bottom numbers are the position of the CpG within the amplicon. CpGs located within
Gamma sequence ends after the 2nd CpG. Each line represents one clone. The bottom figure shows the average methylation at each
CpG site of this locus.
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GAMMA

Figure 36. Methylation of Gamma F2R2 in RWPE. Open circles: Unmethylated CpGs; Closed circles: Methylated CpGs. Top
numbers represent CpG numbers while the bottom numbers are the position of the CpG within the amplicon. CpGs located within
Gamma sequence ends after the 2nd CpG. Each line represents one clone. The bottom figure shows the average methylation at each
CpG site of this locus.
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GAMMA

Figure 37. Methylation of Gamma F2R2 in LNCAP. Open circles: Unmethylated CpGs; Closed circles: Methylated CpGs. Top
numbers represent CpG numbers while the bottom numbers are the position of the CpG within the amplicon. CpGs located within
Gamma sequence ends after the 2nd CpG. Each line represents one clone. The bottom figure shows the average methylation at each
CpG site of this locus.

65

GAMMA

Figure 38. Methylation of Gamma F2R2 in PC3. Open circles: Unmethylated CpGs; Closed circles: Methylated CpGs. Top numbers
represent CpG numbers while the bottom numbers are the position of the CpG within the amplicon. CpGs located within Gamma
sequence ends after the 2nd CpG. Each line represents one clone. The bottom figure shows the average methylation at each CpG site of
this locus.
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GAMMA

Figure 39. Methylation of Gamma F2R2 in DU145. Open circles: Unmethylated CpGs; Closed circles: Methylated CpGs. Top
numbers represent CpG numbers while the bottom numbers are the position of the CpG within the amplicon. CpGs located within
Gamma sequence ends after the 2nd CpG. Each line represents one clone. The bottom figure shows the average methylation at each
CpG site of this locus.
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Figure 40. Methylation of Gamma F3R3 in WAV. Open circles: Unmethylated CpGs; Closed circles: Methylated CpGs. Top numbers
represent CpG numbers while the bottom numbers are the position of the CpG within the amplicon. All sequence are part of Gamma
repeats. Each line represents one clone. The bottom figure shows the average methylation at each CpG site of this locus.
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Figure 41. Methylation of Gamma F3R3 in WBC. Open circles: Unmethylated CpGs; Closed circles: Methylated CpGs. Top numbers
represent CpG numbers while the bottom numbers are the position of the CpG within the amplicon. All sequence are part of Gamma
repeats. Each line represents one clone. The bottom figure shows the average methylation at each CpG site of this locus.
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WAV-17

WBC

Placenta

RWPE-1

LNCAP

PC-3

DU145

G.F1R1

97.4%

97.3%

79.9%/92.1%

65.5%/92.8%

83.3%/88.3%

81.9%/93.3%

83.3%/94.7%

G.F2R2

100%

95.1%

92.1%

93.1%

88.9%

98.6%

94.7%

G.F3R3

98.5%

96.5%

N/A

N/A

N/A

N/A

N/A

Table 4. Total Percent Methylation of Gamma Loci. The percent methylation for each locus on a given template across all clones
collected. Locus 1 contains two methylation values. The first value indicates the total methylation percentage for the long clones while
the second value indicates the total methylation for the short clones. N/A for locus 3 indicates that this amplicon cannot be amplified
for the given templates.
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CHAPTER FOUR
DISCUSSION
NBL2 Satellite
Maps of heterochromatic regions of the human genome, including HC21p, are still only
partially completed (Ziccardi et al., 2016). To date, the exact locations of NBL2 sequences on
the various chromosomes, 9, 13, 14, 15, 21 and Y (Fig. 4) have not been found. The work of
Nishiyama et al. (2005) suggested that NBL2 is located near the centromeres of these
chromosomes. To confirm this and to get higher resolution of NBL2’s location, we used hybrid
cell line mapping to locate the NBL2 region on HC21p. This was done by comparing PCR
results against the HC21p hybrid cell line map (Fig. 17) to deduce the location. The three primer
sets used in this study all agreed that the NBL2 location is near the centromere (Figs., 18-29),
which is in agreement with Nishiyama’s study (2005). The unexpected extra PCR fragments in
one case are from other chromosomes contaminating some hybrid cell lines (Fig.18). These
NBL2 loci were then mapped via Genome Browser for a more precise location on HC21p. The
chromosome coordinates of these primers (Table 1) suggest that NBL2 is located further distal
from the centromere on HC21p (USCS Genome Browser) more than 1Mb from the centromere ,
which is further out than previously assumed.
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The primers I developed for DNA methylation analysis of NBL2 were used by other workers in
our lab. That work showed high methylation in all normal and prostate cancer cell lines, so these
loci would not be useful for biomarker analysis (unpublished data).
Gamma Satellite
DNA methylation is one of the most important epigenetic mechanisms in the human
genome. It maintains genomic stability, preventing chromosomal rearrangements (Ehrlich,
2002), and plays a key role in suppressing transcription of specific genome regions. It has been
seen that the loss of methylation leads to a greater chance for mutations, including those leading
to cancer development (Ehrlich, 2002). The decrease in methylation is one of the many
characteristics in cancer, with more hypomethylation in the more aggressive form of cancer
(Ehrlich, 2002). Since the methylation patterns of a particular sequence are distinct in cancer, the
goal of the present study is to determine if gamma satellite is a potential sequence that can serve
as a biomarker for prostate cancer.
After analyzing the results of the methylation data of all three gamma loci, it appears that
gamma satellite is not a potential biomarker. The overall percent methylation for these sequences
was quite similar in the various prostate cancer cell types (Table 4). The loci used were highly
hypermethylated in all cells. For example, consider comparing the methylation patterns of
gamma F2R2 in RWPE-1 with gamma F2R2 in DU-145. The RWPE-1 cell line is the least
aggressive form of prostate cancer, while DU-145 is the most aggressive form. The methylation
percentage of gamma F2R2 is 93.1% and the methylation percentage of gamma F2R2 is 94.7%.
Thus, there is not much of a difference in gamma methylation between prostate cancers of
differing severity (Table 4).
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Gamma satellite is also hypermethylated in placenta in the both long and short clones
(Table 4), which makes it distinct from most other regions of the genome, which are usually
hypomethylated in placenta. This suggests that gamma satellite is a highly regulated region in the
genome whose hypermethylation is important for genomic function. The hypermethylation of
gamma satellite in all cell types, both normal and cancer, suggests that gamma satellite is
epigenetically a highly stable genomic region that does not play a role during tumorigenesis and
thus is not a useful biomarker.
Gamma Satellite and Function
Gamma satellite is located in the pericentromeric region of almost all of the
chromosomes in the genome. According to Kim et al. (2009), gamma satellite has an
antisilencing activity to prevent the spread of centromeric heterochromatin into the long arm of
the chromosome. In contrast to other satellite families located in the pericentromeric regions,
gamma satellite has both histone modifications characteristic of both euchromatin and
heterochromatin. Kim et al. (2009) found gamma satellite on the X chromosome of human
primary dermal fibroblasts to be enriched in euchromatin histone modification, but it contained
heterochromatin modifications in fibrosarcoma. This finding suggests that the gamma satellite
chromatin state is cell dependent and behaves like facultative heterochromatin. Whether gamma
satellite is assembled into euchromatin or heterochromatin depends on its interaction with other
binding proteins (Kim et al., 2009).
A study done by Ting et al. (2005) agreed with the results of the current study that
gamma satellite is hypermethylated in cancer cells. However, H3K27Ac histone modification, a
euchromatin mark was found in the gamma satellite domain on H21 in fibroblasts using the
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Genome Database. Since this means that gamma satellite is DNA hypermethylated while also
having euchromatin histone modification, the present study is in agreement with Kim et al.
(2009) that gamma satellite is facultative heterochromatin and can behave as euchromatin or
heterochromatin depending on its genetic background. The present study thus suggests that the
stable DNA methylation of gamma satellite may play a major role in the antisilencing boundary
rather than histone modifications.
Limitations of the Study
Repetitive DNA is very hard to work with. The nature of the difficulty in working with
heterochromatic genomic regions begins in the primer design stage. The tandem repeats made it
extremely hard to design primers that were specific to one location on HC21. Since the repeats of
the gamma satellite are highly similar, it was nearly impossible to design primer sets that only
will pick up the desired amplicon. However, after aligning the entire gamma repeats and finding
the few mismatches among the repeats, the three different gamma primer sets were derived using
those mismatches.
Along with the difficulty of primer design, amplification of the designed amplicons
proved to be difficult as well. It was especially difficult to get the amplification of the different
loci when using the diploid templates. This can be seen for gamma F1R1 and F3R3. For gamma
F1R1, it was possible to get the desired 694 bps amplicon. However, there was also a second
band that was amplified during the PCR run that was about 445 bps. Since both bands were
amplified, the longer amplicon had to be isolated and then cloned. Gel extraction was the method
used for the isolation. This process also proved difficult to work with because the amplification
product extracted did not clone and sequence well. Nevertheless, this method did provide the
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clones needed for methylation analysis. In contrast to gamma F1R1, gamma F3R3 only had
successful amplification with WAV-17 and WBC and no other templates. A possible reason for
this could be that F3R3 is the primer set that covers the middle region of the array. F3R3 only
contains the gamma tandem repeats and no unique sequence, thus making reproducible
amplification difficult.
Due to the many challenges associated with tandem repeats, there were limitations on the
amount of data obtained. For gamma F1R1, the templates that contained both the shorter and
longer repeats, only 5-6 longer clones were used for methylation analysis as opposed to 12
clones. This was due to the difficulty obtaining the clones from the gel extraction process. The
shortage in the longer clones used for methylation analysis in the prostate cancer cell lines limits
the conclusions that can be drawn from the methylation data. From the few longer clones
obtained for this locus, gamma F1R1 is hypermethylated for placenta and all four of the cancer
cell lines. These observations suggest that gamma satellite does not play a role during
tumergenesis. In addition to the limitations for gamma F1R1, gamma F3R3 also lacked sufficient
data to draw any conclusions. There were only methylation data for WAV-17 and WBC, but
none for placenta or any of the prostate cancer cell lines.
Future Directions
The use of the various hybrid cell lines provided a preliminary location of NBL2 on
HC21p. It maps NBL2 to the pericentromeric p-arm of HC21. NBL2 mapping via Genome
Browser indicates that the NBL2 cluster is farther from the centromere than previously thought.
This is a good start for locating NBL2 on HC21p. Further more precise mapping is needed. DNA
methylation data for all three loci needs to be gathered and analyzed to determine the overall
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methylation pattern of this sequence. Preliminary data from other work in our lab indicates high
methylation in all normal and prostate cancer cell lines in two NBL2 loci. This indicate that these
loci are not useful as a biomarker. More methylation data are needed on different loci across the
NBL2 array to determine its ultimate potential uses as a biomarker.
In regards to the gamma satellite, a more extensive study needs to be done in order to rule
out its potential as a biomarker for prostate cancer. With the limited data available in this study,
it appears that methylation changes are not a factor in the progression of prostate cancer. Since
the sample size for this study is small, the data might not represent an actual conclusion. To get a
better understanding of the methylation status of gamma satellite in prostate cancer, the sample
size should be increased and the methylation patterns should also be examined in actual prostate
tissues in addition to the cells lines. The tissues will provide an accurate representation of the
methylation patterns in vivo.
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